Top

Journal of Cardiovascular Translational Research

Published in:

01-04-2020 | Arterial Occlusive Disease | Original Article

Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis

Authors: Weilin Tong, Yaqi Duan, Rumeng Yang, Ying Wang, Changqing Peng, Zitian Huo, Guoping Wang

Published in: Journal of Cardiovascular Translational Research | Issue 2/2020

Abstract

CXC chemokine family has been related to atherogenesis for long. However, the relationship between CXCL14 and atherogenesis is still unclear. This study preliminarily detected CXCL14 expression at foam cells in atherosclerosis specimens by immunohistochemistry. In vitro foam cells were derived from THP-1 after phorbol-12-myristate-13-acetate (PMA) and oxidized low-density lipoprotein (ox-LDL) stimulation. Immunoblotting and qPCR convinced CXCL14 expression variation during foam cell formation. We further demonstrated that ox-LDL regulated CXCL14 expression by AP-1. AP-1 could bind to CXCL14 promoter and up-regulate CXCL14 mRNA expression. Besides, CXCL14 promoted THP-1 migration, macrophage lipid phagocytosis, and smooth muscle cell migration as well as proliferation mainly via the ERK1/2 pathway. Additionally, a CXCL14 peptide-induced immune therapy showed efficacy in ApoE^−/− mouse model. In conclusion, our study demonstrated that CXCL14 is highly up-regulated during foam cell formation and promotes atherogenesis in various ways. CXCL14 may be a potent therapeutic target for atherosclerosis.

Available only for authorised users

Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.[J]. European Heart Journal, 38, 2459–2472.CrossRef

Cao Dian, J. (2018). Macrophages in cardiovascular homeostasis and disease.[J]. Circulation, 138, 2452–2455.CrossRef

Tabas, I., & Lichtman, A. H. (2017). Monocyte-macrophages and T cells in atherosclerosis.[J]. Immunity, 47, 621–634.CrossRef

Puca, A. A., Carrizzo, A., Spinelli, C., et al. (2019). Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism.[J]. European Heart Journal published ahead of time.

Li, X., Kemmer, L., Zhang, X., et al. (2018). Anti-inflammatory effects on atherosclerotic lesions induced by CXCR4-directed endoradiotherapy.[J]. Journal of the American College of Cardiology, 72, 122–123.CrossRef

Sainz, J., & Sata, M. (2007). CXCR4, a key modulator of vascular progenitor cells.[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 263–265.CrossRef

Merckelbach, S., van der Vorst, E. P. C., Kallmayer, M., et al. (2018). Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques.[J]. Thrombosis and Haemostasis, 118, 195–206.CrossRef

Salogni, L., Musso, T., Bosisio, D., et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood, 113(23), 5848–5856.

Lu, J., Chatterjee, M., Schmid, H., et al. CXCL14 as an emerging immune and inflammatory modulator. Journal of Inflammation (Lond)., 13, 1.

10.

Sleeman, M. A., Fraser, J. K., Murison, J. G., Kelly, S. L., et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alphachemokine. International Immunology, 12(5), 677–689.

11.

Frederick, M. J., Henderson, Y., et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. The American Journal of Pathology, 156(6), 1937–1950.

12.

Kurth, I., Willimann, K., Schaerli, P., et al. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. The Journal of Experimental Medicine, 194(6), 855–861.

13.

Ozawa, S., Kato, Y., Komori, R., et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochemical and Biophysical Research Communications, 348(2), 406–412.

14.

Tessema, M., Klinge, D. M., Yingling, C. M., et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene., 29(37), 5159–5170.

15.

Song, E. Y., Shurin, M. R., Tourkova, I. L., et al. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Research, 70(11), 4394–4401.

16.

Nara, N., Nakayama, Y., Okamoto, S., et al. (2007). Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance.[J]. The Journal of Biological Chemistry, 282, 30794–30803.CrossRef

17.

Tanegashima, K., Suzuki, K., Nakayama, Y., et al. (2010). Antibody-assisted enhancement of biological activities of CXCL14 in human monocytic leukemia-derived THP-1 cells and high fat diet-induced obese mice.[J]. Experimental Cell Research, 316, 1263–1270.CrossRef

18.

Poon, W.-L., Alenius, H., Ndika, J., et al. (2017). Nano-sized zinc oxide and silver, but not titanium dioxide, induce innate and adaptive immunity and antiviral response in differentiated THP-1 cells.[J]. Nanotoxicology, 11, 936–951.CrossRef

19.

Pelicano, H., et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Research, 69(6), 2375–2383.

20.

Foncea, R., Mazière, C., et al. Endothelial cell oxidative stress and signal transduction. Biological Research, 33(2), 89–96.

21.

Suxia, M., Zhifeng, B., et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB. European Journal of Pharmacology, 851, 186–193.

22.

Sterner, R. M., Takahashi, P. Y., Yu, B., & Aimee, C. (2016). Active vaccines for Alzheimer disease treatment.[J]. Journal of the American Medical Directors Association, 17, 862.e11–862.e15.CrossRef

Title: Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis
Authors: Weilin Tong
Yaqi Duan
Rumeng Yang
Ying Wang
Changqing Peng
Zitian Huo
Guoping Wang
Publication date: 01-04-2020
Publisher: Springer US
Keyword: Arterial Occlusive Disease
Published in: Journal of Cardiovascular Translational Research / Issue 2/2020
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-019-09915-z

2024 ASCO Annual Meeting

Springer Medicine

Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Extracellular Vesicles as Messengers in Atherosclerosis

Preoperative miRNA-208a as a Predictor of Postoperative Complications in Children with Congenital Heart Disease Undergoing Heart Surgery

Heterogeneous Outcomes of Heart Failure with Better Ejection Fraction

The Role of Deubiquitinases in Vascular Diseases

Novel Embolic Protection Device: a Feasibility Study

Effects of Adiponectin on Diastolic Function in Mice Underwent Transverse Aorta Constriction